ALX Oncology Holdings Inc. announced the pricing of an underwritten offering consisting of 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares of common stock. The shares are being sold at $1.57 per share, while the pre-funded warrants are priced at $1.569 per warrant. The offering is expected to raise approximately $150 million in gross proceeds before expenses. The proceeds will be used to fund the continued clinical development of evorpacept and the ALX2004 program, as well as for working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9646140) on January 30, 2026, and is solely responsible for the information contained therein.